WO2001004313A1 - Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence - Google Patents
Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence Download PDFInfo
- Publication number
- WO2001004313A1 WO2001004313A1 PCT/US2000/017670 US0017670W WO0104313A1 WO 2001004313 A1 WO2001004313 A1 WO 2001004313A1 US 0017670 W US0017670 W US 0017670W WO 0104313 A1 WO0104313 A1 WO 0104313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- strand
- polynucleotide
- terminator
- molecule according
- Prior art date
Links
- 0 CCCC1*(CCCC(CC(CCC=C(C)CC(C)CCCC2)[C@]3Br(C)*C)C3*=C=C*)=CC2C1* Chemical compound CCCC1*(CCCC(CC(CCC=C(C)CC(C)CCCC2)[C@]3Br(C)*C)C3*=C=C*)=CC2C1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA01013462A MXPA01013462A (es) | 1999-07-09 | 2000-06-27 | Metodos y composiciones para prevenir la formacion de arn aberrante durante la transcripcion de una secuencia plasmidica. |
EP00944916A EP1194556A1 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
BR0012325-0A BR0012325A (pt) | 1999-07-09 | 2000-06-27 | Métodos e composições para prevenção da formação de rna anormal durante a transcrição de uma sequência de plasmìdeo |
JP2001509517A JP2003504061A (ja) | 1999-07-09 | 2000-06-27 | プラスミド配列の転写の間における異常型rnaの形成を防止するための方法および組成物 |
IL14702600A IL147026A0 (en) | 1999-07-09 | 2000-06-27 | Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence |
CA002378653A CA2378653A1 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
KR1020027000339A KR20020030780A (ko) | 1999-07-09 | 2000-06-27 | 플라스미드 서열의 전사 동안 비정상적인 rna 형성을예방하기 위한 방법 및 조성물 |
AU58937/00A AU783681B2 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant RNA during transcription of a plasmid sequence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14305999P | 1999-07-09 | 1999-07-09 | |
US60/143,059 | 1999-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001004313A1 true WO2001004313A1 (en) | 2001-01-18 |
Family
ID=22502421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/017670 WO2001004313A1 (en) | 1999-07-09 | 2000-06-27 | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1194556A1 (zh) |
JP (1) | JP2003504061A (zh) |
KR (1) | KR20020030780A (zh) |
CN (1) | CN1360631A (zh) |
AU (1) | AU783681B2 (zh) |
BR (1) | BR0012325A (zh) |
CA (1) | CA2378653A1 (zh) |
IL (1) | IL147026A0 (zh) |
MX (1) | MXPA01013462A (zh) |
WO (1) | WO2001004313A1 (zh) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001068835A2 (en) * | 2000-03-13 | 2001-09-20 | Aptagen | Method for modifying a nucleic acid |
WO2002098443A2 (de) * | 2001-06-05 | 2002-12-12 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/ c- gehalt und otimierter codon usage für die gentherapie |
US6630589B1 (en) | 2001-03-26 | 2003-10-07 | Message Pharmaceuticals | Identification of compounds for the treatment or prevention of proliferative diseases |
WO2005028649A1 (en) | 2002-02-20 | 2005-03-31 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005118787A2 (en) | 2004-05-10 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
EP1623009A2 (en) * | 2003-04-22 | 2006-02-08 | Nucleonics, Inc | Transfection kinetics and structural promoters |
WO2008092153A2 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
WO2008116094A2 (en) | 2007-03-21 | 2008-09-25 | Brookhaven Science Associates, Llc | Combined hairpin-antisense compositions and methods for modulating expression |
EP2042510A2 (en) | 2002-02-20 | 2009-04-01 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
US7858625B2 (en) | 2001-05-18 | 2010-12-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
US7888325B2 (en) | 1999-01-28 | 2011-02-15 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
WO2011073326A2 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8217016B2 (en) | 2001-12-19 | 2012-07-10 | Curevac Gmbh | Application of mRNA for use as a therapeutic agent for tumorous diseases |
EP2484780A1 (en) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Methods and materials for determining pain sensibility and predicting and treating related disorders |
US8299042B2 (en) | 2002-04-26 | 2012-10-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for silencing genes without inducing toxicity |
US8329667B2 (en) | 2004-04-23 | 2012-12-11 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
US8476245B2 (en) | 2004-02-11 | 2013-07-02 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti matrix metalloproteinase DNAzymes |
WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
US8703769B2 (en) | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8883996B2 (en) | 2007-05-01 | 2014-11-11 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP1685844B1 (de) | 2002-07-03 | 2015-03-18 | CureVac GmbH | Immunstimulation durch chemisch modifizierte RNA |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9029527B2 (en) | 1998-03-20 | 2015-05-12 | Commonwealth Scientific And Industrial Research Organisation | Synthetic genes and genetic constructs |
US9051566B2 (en) | 2001-01-31 | 2015-06-09 | Alnylam Pharmaceuticals, Inc. | Post-transcriptional gene silencing using expressed double stranded RNA |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
EP2980220A1 (en) | 2005-09-20 | 2016-02-03 | BASF Plant Science GmbH | Improved methods controlling gene expression |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9708621B2 (en) | 1999-08-13 | 2017-07-18 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
WO2017152073A1 (en) | 2016-03-04 | 2017-09-08 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels) |
US9963698B2 (en) | 1998-03-20 | 2018-05-08 | Commonwealth Scientific And Industrial Research Organisation | Control of gene expression |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2020236597A1 (en) * | 2019-05-17 | 2020-11-26 | Massachusetts Institute Of Technology | Engineered post-poly a signal rna and uses thereof |
US10898584B2 (en) | 2013-11-01 | 2021-01-26 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029244A1 (en) * | 1994-04-26 | 1995-11-02 | Wisconsin Alumni Research Foundation | Method to increase regulatory molecule production |
WO1996019573A1 (en) * | 1994-12-19 | 1996-06-27 | Cangene Corporation | Recombinant dna molecules and expression vectors for erythropoietin |
WO1997044450A1 (en) * | 1996-05-21 | 1997-11-27 | Yale University | Regulation of gene expression |
WO1999010509A1 (en) * | 1997-08-22 | 1999-03-04 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Polynucleotide inhibition of rna destabilization and sequestration |
WO1999014346A2 (en) * | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | SENSE mRNA THERAPY |
-
2000
- 2000-06-27 EP EP00944916A patent/EP1194556A1/en not_active Withdrawn
- 2000-06-27 AU AU58937/00A patent/AU783681B2/en not_active Ceased
- 2000-06-27 JP JP2001509517A patent/JP2003504061A/ja active Pending
- 2000-06-27 BR BR0012325-0A patent/BR0012325A/pt not_active IP Right Cessation
- 2000-06-27 MX MXPA01013462A patent/MXPA01013462A/es unknown
- 2000-06-27 KR KR1020027000339A patent/KR20020030780A/ko not_active Application Discontinuation
- 2000-06-27 WO PCT/US2000/017670 patent/WO2001004313A1/en not_active Application Discontinuation
- 2000-06-27 CA CA002378653A patent/CA2378653A1/en not_active Abandoned
- 2000-06-27 CN CN00810072A patent/CN1360631A/zh active Pending
- 2000-06-27 IL IL14702600A patent/IL147026A0/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029244A1 (en) * | 1994-04-26 | 1995-11-02 | Wisconsin Alumni Research Foundation | Method to increase regulatory molecule production |
WO1996019573A1 (en) * | 1994-12-19 | 1996-06-27 | Cangene Corporation | Recombinant dna molecules and expression vectors for erythropoietin |
WO1997044450A1 (en) * | 1996-05-21 | 1997-11-27 | Yale University | Regulation of gene expression |
WO1999010509A1 (en) * | 1997-08-22 | 1999-03-04 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Polynucleotide inhibition of rna destabilization and sequestration |
WO1999014346A2 (en) * | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | SENSE mRNA THERAPY |
Non-Patent Citations (8)
Title |
---|
ANDRE S ET AL: "INCREASED IMMUNE RESPONSE ELICITED BY DNA VACCINATION WITH A SYNTHETIC GP120 SEQUENCE WITH OPTIMIZED CODON USAGE", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 2, 1 February 1998 (1998-02-01), pages 1497 - 1503, XP002073767, ISSN: 0022-538X * |
BAHRAMIAN MOHAMMAD B ET AL: "Transcriptional and posttranscriptional silencing of rodent alpha1(I) collagen by a homologous transcriptionally self-silenced transgene.", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 1, January 1999 (1999-01-01), pages 274 - 283, XP002151089, ISSN: 0270-7306 * |
CAMERON F H ET AL: "INHIBITION OF GENE EXPRESSION BY A SHORT SENSE FRAGMENT", NUCLEIC ACIDS RESEARCH, vol. 19, no. 3, 1991, pages 469 - 475, XP002151090, ISSN: 0305-1048 * |
ENRIQUEZ-HARRIS P ET AL: "A PAUSE SITE FOR RNA POLYMERASE II IS ASSOCIATED WITH TERMINATION OF TRANSCRIPTION", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 10, no. 7, 1991, pages 1833 - 1842, XP002151088, ISSN: 0261-4189 * |
L. TIMMONS AND A. FIRE: "Specific interference by ingested dsRNA", NATURE, vol. 395, 29 October 1998 (1998-10-29), MACMILLAN JOURNALS LTD., LONDON,UK, pages 854, XP002151091 * |
MISQUITTA LEONIE ET AL: "Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): A role for nautilus in embryonic somatic muscle formation.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 4, 16 February 1999 (1999-02-16), Feb. 16, 1999, pages 1451 - 1456, XP002151092, ISSN: 0027-8424 * |
NILSSON M ET AL: "PADLOCK PROBES: CIRCULARIZING OLIGONUCLEOTIDES FOR LOCALIZED DNA DETECTION", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 265, no. 5181, 30 September 1994 (1994-09-30), pages 2085 - 2088, XP000579803, ISSN: 0036-8075 * |
ZOLOTUKHIN S ET AL: "A HUMANIZED GREEN FLUORESCENT PROTEIN CDNA ADAPTED FOR HIGH-LEVEL EXPRESSION IN MAMMALIAN CELLS", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 70, no. 7, 1 July 1996 (1996-07-01), pages 4646 - 4654, XP002030427, ISSN: 0022-538X * |
Cited By (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029527B2 (en) | 1998-03-20 | 2015-05-12 | Commonwealth Scientific And Industrial Research Organisation | Synthetic genes and genetic constructs |
US9963698B2 (en) | 1998-03-20 | 2018-05-08 | Commonwealth Scientific And Industrial Research Organisation | Control of gene expression |
US7888325B2 (en) | 1999-01-28 | 2011-02-15 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US8148345B2 (en) | 1999-01-28 | 2012-04-03 | Georgia Health Sciences University Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
US8367630B2 (en) | 1999-03-17 | 2013-02-05 | The University Of North Carolina At Chapel Hill | Method for inhibiting expression of a protein in a hepatocyte |
US10190127B2 (en) | 1999-08-13 | 2019-01-29 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
US9708621B2 (en) | 1999-08-13 | 2017-07-18 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
WO2001068835A2 (en) * | 2000-03-13 | 2001-09-20 | Aptagen | Method for modifying a nucleic acid |
WO2001068835A3 (en) * | 2000-03-13 | 2003-01-30 | Aptagen | Method for modifying a nucleic acid |
US9051566B2 (en) | 2001-01-31 | 2015-06-09 | Alnylam Pharmaceuticals, Inc. | Post-transcriptional gene silencing using expressed double stranded RNA |
US6630589B1 (en) | 2001-03-26 | 2003-10-07 | Message Pharmaceuticals | Identification of compounds for the treatment or prevention of proliferative diseases |
US7858625B2 (en) | 2001-05-18 | 2010-12-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US11135312B2 (en) | 2001-06-05 | 2021-10-05 | Curevac Ag | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
US10188748B2 (en) | 2001-06-05 | 2019-01-29 | Curevac Ag | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
EP1832603A3 (de) * | 2001-06-05 | 2007-10-31 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
EP1903054A3 (de) * | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
EP1800697A3 (de) * | 2001-06-05 | 2007-10-31 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
EP1832603A2 (de) * | 2001-06-05 | 2007-09-12 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
EP1857122A3 (de) * | 2001-06-05 | 2008-11-19 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
US11369691B2 (en) | 2001-06-05 | 2022-06-28 | Curevac Ag | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
WO2002098443A2 (de) * | 2001-06-05 | 2002-12-12 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/ c- gehalt und otimierter codon usage für die gentherapie |
EP1800697A2 (de) * | 2001-06-05 | 2007-06-27 | CureVac GmbH | Pharmazeutische Zusammensetzung, enthaltend eine stabilisierte und für die Translation in ihren codierenden Bereichen optimierte mRNA |
EP1604688A1 (de) * | 2001-06-05 | 2005-12-14 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
EP2842964A1 (de) * | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
WO2002098443A3 (de) * | 2001-06-05 | 2003-11-13 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/ c- gehalt und otimierter codon usage für die gentherapie |
EP1857122A2 (de) * | 2001-06-05 | 2007-11-21 | CureVac GmbH | Pharmazeutische Zusammensetzung, enthaltend eine stabilisierte und für die Translation in ihren codierenden Bereichen optimierte mRNA |
US10568972B2 (en) | 2001-06-05 | 2020-02-25 | Curevac Ag | Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions |
EP2305699A1 (de) * | 2001-06-05 | 2011-04-06 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
US7527945B2 (en) | 2001-10-22 | 2009-05-05 | Nucleonics, Inc. | Transfection kinetics and structural promoters |
US9433670B2 (en) | 2001-12-19 | 2016-09-06 | Curevac Ag | Application of mRNA for use as a therapeutic against tumour diseases |
US9433669B2 (en) | 2001-12-19 | 2016-09-06 | Curevac Ag | Application of mRNA for use as a therapeutic against tumor diseases |
US9439956B2 (en) | 2001-12-19 | 2016-09-13 | Curevac Ag | Application of mRNA for use as a therapeutic against tumour diseases |
US9155788B2 (en) | 2001-12-19 | 2015-10-13 | Curevac Gmbh | Application of mRNA for use as a therapeutic against tumour diseases |
US8217016B2 (en) | 2001-12-19 | 2012-07-10 | Curevac Gmbh | Application of mRNA for use as a therapeutic agent for tumorous diseases |
US9463228B2 (en) | 2001-12-19 | 2016-10-11 | Curevac Ag | Application of mRNA for use as a therapeutic against tumour diseases |
US9655955B2 (en) | 2001-12-19 | 2017-05-23 | Curevac Ag | Application of mRNA for use as a therapeutic against tumour diseases |
US8846894B2 (en) | 2002-02-20 | 2014-09-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2042510A2 (en) | 2002-02-20 | 2009-04-01 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP3354656A1 (en) | 2002-02-20 | 2018-08-01 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2287305A1 (en) | 2002-02-20 | 2011-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2287306A1 (en) | 2002-02-20 | 2011-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
EP2278004A1 (en) | 2002-02-20 | 2011-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2005028649A1 (en) | 2002-02-20 | 2005-03-31 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2902406A1 (en) | 2002-02-20 | 2015-08-05 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
EP3926046A2 (en) | 2002-02-20 | 2021-12-22 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
EP3459963A1 (en) | 2002-02-20 | 2019-03-27 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US7176304B2 (en) | 2002-02-20 | 2007-02-13 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US8299042B2 (en) | 2002-04-26 | 2012-10-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for silencing genes without inducing toxicity |
EP2216028B1 (de) | 2002-07-03 | 2017-12-06 | CureVac AG | Immunstimulation durch chemisch modifizierte eingelsträngige RNA |
EP1797886B1 (de) | 2002-07-03 | 2019-07-10 | CureVac AG | Immunstimulation durch chemisch modifizierte RNA |
EP1685844B1 (de) | 2002-07-03 | 2015-03-18 | CureVac GmbH | Immunstimulation durch chemisch modifizierte RNA |
EP1623009A2 (en) * | 2003-04-22 | 2006-02-08 | Nucleonics, Inc | Transfection kinetics and structural promoters |
EP1623009A4 (en) * | 2003-04-22 | 2008-02-13 | Nucleonics Inc | TRANSFECTION KINETICS AND STRUCTURAL PROMOTERS |
US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
US8476245B2 (en) | 2004-02-11 | 2013-07-02 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti matrix metalloproteinase DNAzymes |
US9365849B2 (en) | 2004-03-15 | 2016-06-14 | Integrated Dna Technologies, Inc. | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US10106792B2 (en) | 2004-03-15 | 2018-10-23 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US9988630B2 (en) | 2004-03-15 | 2018-06-05 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8658356B2 (en) | 2004-03-15 | 2014-02-25 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8691786B2 (en) | 2004-03-15 | 2014-04-08 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US9518262B2 (en) | 2004-03-15 | 2016-12-13 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8796444B2 (en) | 2004-03-15 | 2014-08-05 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8809515B2 (en) | 2004-03-15 | 2014-08-19 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8329667B2 (en) | 2004-04-23 | 2012-12-11 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
US8946402B2 (en) | 2004-04-23 | 2015-02-03 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
WO2005118787A2 (en) | 2004-05-10 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP2484780A1 (en) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Methods and materials for determining pain sensibility and predicting and treating related disorders |
US8703769B2 (en) | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
EP2980220A1 (en) | 2005-09-20 | 2016-02-03 | BASF Plant Science GmbH | Improved methods controlling gene expression |
WO2008092153A2 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
WO2008116094A2 (en) | 2007-03-21 | 2008-09-25 | Brookhaven Science Associates, Llc | Combined hairpin-antisense compositions and methods for modulating expression |
US9193972B2 (en) | 2007-03-21 | 2015-11-24 | Brookhaven Science Associates, Llc | Combined hairpin-antisense compositions and methods for modulating expression |
US8796442B2 (en) | 2007-03-21 | 2014-08-05 | Brookhaven Science Associates, Llc. | Combined hairpin-antisense compositions and methods for modulating expression |
US9873875B2 (en) | 2007-05-01 | 2018-01-23 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US10233450B2 (en) | 2007-05-01 | 2019-03-19 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US8883996B2 (en) | 2007-05-01 | 2014-11-11 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
US9441227B2 (en) | 2007-05-01 | 2016-09-13 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
EP3000885A2 (en) | 2009-12-18 | 2016-03-30 | Arrowhead Research Corporation | Organic compositions to treat hsf1-related diseases |
EP3406720A1 (en) | 2009-12-18 | 2018-11-28 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
WO2011073326A2 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
EP3766976A1 (en) | 2009-12-18 | 2021-01-20 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9181319B2 (en) | 2010-08-06 | 2015-11-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9937233B2 (en) | 2010-08-06 | 2018-04-10 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10064959B2 (en) | 2010-10-01 | 2018-09-04 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9657295B2 (en) | 2010-10-01 | 2017-05-23 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9050297B2 (en) | 2012-04-02 | 2015-06-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator |
US9587003B2 (en) | 2012-04-02 | 2017-03-07 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9061059B2 (en) | 2012-04-02 | 2015-06-23 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating protein deficiency |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9089604B2 (en) | 2012-04-02 | 2015-07-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for treating galactosylceramidase protein deficiency |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10898584B2 (en) | 2013-11-01 | 2021-01-26 | Curevac Ag | Modified RNA with decreased immunostimulatory properties |
WO2017152073A1 (en) | 2016-03-04 | 2017-09-08 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels) |
WO2020236597A1 (en) * | 2019-05-17 | 2020-11-26 | Massachusetts Institute Of Technology | Engineered post-poly a signal rna and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
IL147026A0 (en) | 2002-08-14 |
CN1360631A (zh) | 2002-07-24 |
MXPA01013462A (es) | 2002-07-02 |
AU783681B2 (en) | 2005-11-24 |
CA2378653A1 (en) | 2001-01-18 |
BR0012325A (pt) | 2002-05-21 |
JP2003504061A (ja) | 2003-02-04 |
AU5893700A (en) | 2001-01-30 |
EP1194556A1 (en) | 2002-04-10 |
KR20020030780A (ko) | 2002-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU783681B2 (en) | Methods and compositions for preventing the formation of aberrant RNA during transcription of a plasmid sequence | |
KR102580696B1 (ko) | 신규 인공 핵산 분자 | |
Cottard et al. | Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis | |
EP3768846B1 (en) | Viral and non-viral nanoplasmid vectors with improved production | |
JP2016104027A (ja) | mRNA翻訳エンハンサーエレメントに関する組成物および方法 | |
EP1844142B1 (en) | Vectors and methods for genetic immunization | |
CN112226461B (zh) | Cd4阳性细胞特异性基因传递载体及其应用 | |
CN112725342A (zh) | 一种启动子pCALM2及其应用 | |
SK181498A3 (en) | Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition | |
EP1075529A1 (en) | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress | |
WO2019139227A1 (en) | Gene expression cassette and expression vector including the same | |
KR101442254B1 (ko) | 최적의 진핵 세포 발현 벡터의 개발 | |
CN113874512A (zh) | 诱导毛细胞分化的组合物和方法 | |
WO2006056825A1 (en) | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress | |
US20060171924A1 (en) | Bidirectional promoters for small RNA expression | |
Huang | Molecular modulation of allergic responses | |
TWI260346B (en) | Internal ribosome entry site of the labial gene for protein expression | |
US7034142B1 (en) | Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins | |
CN114908089B (zh) | 3’utr的构建方法和应用 | |
WO2002050264A2 (en) | Promoters and recombinant expression constructs | |
Nordstrom | Expression plasmids for non-viral gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 58937/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/013462 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000944916 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008100721 Country of ref document: CN Ref document number: 2378653 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027000339 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000944916 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027000339 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 58937/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000944916 Country of ref document: EP |